Nanobiotix (NBTX) News Today $5.16 0.00 (0.00%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 6, 2024 | marketbeat.comNanobiotix (NASDAQ:NBTX) Trading Up 1.2%Nanobiotix (NASDAQ:NBTX) Trading Up 1.2%June 15, 2024 | marketbeat.comNanobiotix (NASDAQ:NBTX) Stock Price Down 14%Nanobiotix (NASDAQ:NBTX) Trading Down 14%June 12, 2024 | globenewswire.comNANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024June 2, 2024 | globenewswire.comNanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 TherapyMay 28, 2024 | globenewswire.comNANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference CallMay 24, 2024 | marketbeat.comLeerink Partnrs Comments on Nanobiotix S.A.'s FY2025 Earnings (NASDAQ:NBTX)Nanobiotix S.A. (NASDAQ:NBTX - Free Report) - Leerink Partnrs dropped their FY2025 earnings per share (EPS) estimates for Nanobiotix in a research report issued to clients and investors on Wednesday, May 22nd. Leerink Partnrs analyst J. Chang now expects that the company will post earnings per shMay 23, 2024 | globenewswire.comNANOBIOTIX to Present at the Jefferies Global Healthcare ConferenceMay 22, 2024 | finanznachrichten.deNanobiotix S.A.: Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term GrowthMay 22, 2024 | globenewswire.comNANOBIOTIX Provides First Quarter 2024 Operational and Financial UpdateMay 21, 2024 | globenewswire.comNanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term GrowthMay 15, 2024 | globenewswire.comNANOBIOTIX to Announce First Quarter Operational and Financial Update on May 22, 2024May 14, 2024 | globenewswire.comNANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung CancerApril 30, 2024 | marketbeat.comNanobiotix's (NBTX) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reaffirmed a "buy" rating on shares of Nanobiotix in a research report on Friday.April 29, 2024 | seekingalpha.comNanobiotix S.A. (NBTX) Q4 2023 Earnings Call TranscriptApril 26, 2024 | benzinga.comNanobiotix Stock (NASDAQ:NBTX), Earnings Estimates, EPS, and RevenueApril 24, 2024 | globenewswire.comNANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial ResultsApril 17, 2024 | globenewswire.comNANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024April 11, 2024 | marketbeat.comBaillie Gifford & Co. Has $20.89 Million Stock Holdings in Nanobiotix S.A. (NASDAQ:NBTX)Baillie Gifford & Co. increased its position in Nanobiotix S.A. (NASDAQ:NBTX - Free Report) by 48.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,869,030 shares of the company's stock after buying an aApril 3, 2024 | marketbeat.comNanobiotix (NASDAQ:NBTX) Trading Down 1.6%Nanobiotix (NASDAQ:NBTX) Trading Down 1.6%April 2, 2024 | globenewswire.comNanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-IrradiationMarch 6, 2024 | globenewswire.comNanobiotix to Present at Upcoming Investor Conferences in MarchFebruary 17, 2024 | marketbeat.comNanobiotix S.A. (NASDAQ:NBTX) Shares Bought by Baillie Gifford & Co.Baillie Gifford & Co. raised its holdings in Nanobiotix S.A. (NASDAQ:NBTX - Free Report) by 38.3% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,936,195 shares of the company's stock after purchaFebruary 12, 2024 | marketbeat.comJohnson & Johnson Buys Shares of 959,637 Nanobiotix S.A. (NASDAQ:NBTX)Johnson & Johnson bought a new stake in Nanobiotix S.A. (NASDAQ:NBTX - Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 959,637 shares of the company's stock, valued at approximately $8,397,000.February 3, 2024 | marketbeat.comNanobiotix (NASDAQ:NBTX) Shares Down 2.3% Nanobiotix (NASDAQ:NBTX) Stock Price Down 2.3%January 31, 2024 | finance.yahoo.comNanobiotix to Present at the Guggenheim 6th Annual Biotechnology ConferenceJanuary 30, 2024 | finanznachrichten.deNanobiotix S.A.: Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer StudyJanuary 29, 2024 | finance.yahoo.comNanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer StudyJanuary 18, 2024 | seekingalpha.comNBTX Nanobiotix S.A.January 12, 2024 | marketbeat.comNanobiotix S.A. (NASDAQ:NBTX) Sees Large Increase in Short InterestNanobiotix S.A. (NASDAQ:NBTX - Get Free Report) saw a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 35,700 shares, an increase of 113.8% from the December 15th total of 16,700 shares. Based on an average trading volume of 19,000 shares, the days-to-cover ratio is currently 1.9 days.December 8, 2023 | realmoney.thestreet.comNanobiotix initiated with an Outperform at LeerinkDecember 4, 2023 | finance.yahoo.comNanobiotix Announces Closing of the Remaining $4.8 Million Investment From Johnson & Johnson Innovation – JJDC, Inc.November 15, 2023 | finanznachrichten.deNanobiotix S.A.: NANOBIOTIX Provides Third Quarter 2023 Operational and Financial UpdateNovember 13, 2023 | finance.yahoo.comNANOBIOTIX Provides Third Quarter 2023 Operational and Financial UpdateNovember 9, 2023 | finance.yahoo.comNANOBIOTIX to Announce Third Quarter 2023 Operational and Financial Update on November 13, 2023November 9, 2023 | finanznachrichten.deNanobiotix S.A.: Voting Rights and Shares Capital of the CompanyNovember 7, 2023 | finance.yahoo.comNANOBIOTIX Announces Closing of Global OfferingNovember 6, 2023 | finance.yahoo.comNANOBIOTIX Announces the Availability of a Prospectus in Connection with Capital Increases Raising Total Gross Proceeds of Approximately $50M and the Exercise by the Underwriters of the Over-Allotment Option for an Additional Amount of Approximately $3.6MNovember 2, 2023 | msn.comWhy Nanobiotix (NBTX) Stock Is Plunging ThursdayNovember 2, 2023 | finance.yahoo.comNANOBIOTIX Announces Pricing of a Capital Increase Raising Total Gross Proceeds of $55MNovember 2, 2023 | morningstar.comNanobiotix SA ADR NBTXNovember 1, 2023 | finance.yahoo.comNANOBIOTIX Announces Launch of Global Follow-On Offering and a Concurrent Private Placement Along with the Removal of the EIB Cash CovenantOctober 23, 2023 | finance.yahoo.comNANOBIOTIX Announces Updated Preliminary Results From Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis From Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023October 5, 2023 | msn.comNanobiotix falls after Phase 1 data for lead asset in head and neck cancerOctober 5, 2023 | markets.businessinsider.comUBS Reaffirms Their Buy Rating on Nanobiotix (NBTX)October 4, 2023 | finance.yahoo.comNanobiotix Announces the Presentation of the Final Efficacy Analysis From Phase 1 Cohort Expansion Evaluating NBTXR3 in Locally Advanced Head and Neck Cancer Showing Median Progression-Free Survival of 16.9 Months and Median Overall Survival of 23.1 MonthsSeptember 29, 2023 | finance.yahoo.comNANOBIOTIX Announces Oral Presentation of Final Results From a Phase 1 Dose Expansion Study Evaluating NBTXR3 in Head and Neck Cancer at the 65th Annual Meeting of the American Society for Radiation OncologySeptember 28, 2023 | finance.yahoo.comNANOBIOTIX Announces Presentation of First Data From Phase 1 Study Evaluating NBTXR3 for Patients With Locally Advanced Pancreatic CancerSeptember 27, 2023 | finanznachrichten.deNanobiotix S.A.: NANOBIOTIX Provides Business Update and Financial Results for the First Half of 2023September 26, 2023 | finance.yahoo.comNANOBIOTIX Provides Business Update and Financial Results for the First Half of 2023September 19, 2023 | finance.yahoo.comNanobiotix to Announce Half Year 2023 Financial Results on September 26, 2023 Get Nanobiotix News Delivered to You Automatically Sign up to receive the latest news and ratings for NBTX and its competitors with MarketBeat's FREE daily newsletter. Email Address “Generational Bull Run” Incoming (Ad)LIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event. You can find out what they are by clicking here now. NBTX Media Mentions By Week NBTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NBTX News Sentiment▼1.870.61▲Average Medical News Sentiment NBTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NBTX Articles This Week▼11▲NBTX Articles Average Week Get Nanobiotix News Delivered to You Automatically Sign up to receive the latest news and ratings for NBTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: OPKO Health News Today ARS Pharmaceuticals News Today Praxis Precision Medicines News Today Centessa Pharmaceuticals News Today Pacira BioSciences News Today AbCellera Biologics News Today Immunome News Today Liquidia News Today Cogent Biosciences News Today Harrow News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NBTX) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nanobiotix S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nanobiotix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.